Number of the records: 1

Development of Small-Molecule Antivirals for Ebola

SYSNO ASEP	0450477
Document Type	J - Journal Article
R&D Document Type	Journal Article
Subsidiary J	Článek ve WOS
Title	Development of Small-Molecule Antivirals for Ebola
Author(s)	Janeba, Zlatko (UOCHB-X)_{RID, ORCID}
Number of authors	1
Source Title	Medicinal Research Reviews. - : Wiley - ISSN 0198-6325 Roč. 35, č. 6 (2015), s. 1175-1194
Number of pages	20 s.
Language	eng - English
Country	US - United States
Keywords	antiviral ; filovirus ; Ebola virus ; Marburg virus ; hemorrhagic fever
Subject RIV	CC - Organic Chemistry
Institutional support	UOCHB-X - RVO:61388963
UT WOS	000362795200004
EID SCOPUS	84943521313
DOI	10.1002/med.21355
Annotation	Ebola hemorrhagic fever is a deadly disease caused by infection with one of the Ebola virus species. Although a significant progress has recently been made in understanding of Ebola virus biology and pathogenesis, development of effective anti-Ebola treatments has not been very productive, compared to other areas of antiviral research (e.g., HIV and HCV infections). No approved vaccine or medicine is available for Ebola but several are currently under development. This review summarises attempts in identification, evaluation, and development of small-molecule candidates for treatment of Ebola viral disease, including the most promising experimental drugs brincidofovir (CMX001), BCX4430, and favipiravir (T-705).
Workplace	Institute of Organic Chemistry and Biochemistry
Contact	asep@uochb.cas.cz ; Kateřina Šperková, Tel.: 232 002 584 ; Viktorie Chládková, Tel.: 232 002 434
Year of Publishing	2016

Number of the records: 1